InBrain Pharma

InBrain Pharma is a clinical-stage biotech company founded in 2018 by Prof. David Devos and Prof. Caroline Moreau at Lille teaching Hospital and Dr. Matthieu Fisichella. InBrain Pharma is developing the concept of cerebral infusion of drugs to treat neurological disease disorders. Its most advanced project concerns the dopamine in anaerobic conditions (A-dopamine) for titrated and individualized administration by the intracerebroventricular (i.c.v.) route for the treatment of severe motor symptoms in Parkinson's patients who have become refractory to L-Dopa and/or dopaminergic agonist-based treatments. InBrain Pharma is a winner of the Lille University Foundation Prize, the ILAB competition and raised its first funds. These funds enabled the company to carry out its first Phase I/IIB clinical trial on 12 patients, the final results have been been published in Nature Medicine in 2025. This trial establishes the safety and beneficial effect of pharmacological neuromodulation with A-dopamine on severe motor symptoms in late-stage Parkinson's patients, and validates the proof-of-concept of brain perfusion of disease-correcting drug agents in neurological diseases. On the strength of these very positive results, InBrain Pharma is committed to moving A-dopamine into Phase III as quickly as possible, and to advancing its other preclinical programs in order to build up its platform of brain-infused drugs.